MX2018004695A - Composiciones de proteinas estables. - Google Patents

Composiciones de proteinas estables.

Info

Publication number
MX2018004695A
MX2018004695A MX2018004695A MX2018004695A MX2018004695A MX 2018004695 A MX2018004695 A MX 2018004695A MX 2018004695 A MX2018004695 A MX 2018004695A MX 2018004695 A MX2018004695 A MX 2018004695A MX 2018004695 A MX2018004695 A MX 2018004695A
Authority
MX
Mexico
Prior art keywords
therapeutic biomolecule
reservoir
biomolecule
therapeutic
porous structure
Prior art date
Application number
MX2018004695A
Other languages
English (en)
Inventor
Chen Hunter
Schlesinger Erica
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018004695A publication Critical patent/MX2018004695A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/08—Polyethers derived from hydroxy compounds or from their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Abstract

Se describen formulaciones farmacéuticas estables y dispositivos de suministro de fármacos. En determinadas modalidades, el dispositivo de suministro de fármacos contiene un depósito cuando se implanta en un paciente que se encuentra en contacto parcial con el entorno del tejido. El depósito permanece en contacto con el entorno a través de una estructura porosa en el alojamiento del dispositivo de suministro. El depósito contiene una combinación de la biomolécula terapéutica y una segunda molécula que funciona para estabilizar y restringir la solubilidad de la biomolécula terapéutica, mediante lo cual se controla la cantidad de biomolécula terapéutica que se encuentra en solución. La concentración de la biomolécula terapéutica soluble o el tamaño del área de superficie de la estructura porosa controla la velocidad de suministro de la biomolécula terapéutica al tejido diana.
MX2018004695A 2015-10-16 2016-10-14 Composiciones de proteinas estables. MX2018004695A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562242412P 2015-10-16 2015-10-16
PCT/US2016/057019 WO2017066554A1 (en) 2015-10-16 2016-10-14 Stable protein compositions

Publications (1)

Publication Number Publication Date
MX2018004695A true MX2018004695A (es) 2019-03-14

Family

ID=57209897

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004695A MX2018004695A (es) 2015-10-16 2016-10-14 Composiciones de proteinas estables.
MX2022003376A MX2022003376A (es) 2015-10-16 2018-04-16 Composiciones de proteinas estables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003376A MX2022003376A (es) 2015-10-16 2018-04-16 Composiciones de proteinas estables.

Country Status (12)

Country Link
US (1) US20180289623A1 (es)
EP (1) EP3362041A1 (es)
JP (3) JP6853245B2 (es)
KR (1) KR20180063311A (es)
CN (2) CN113827704A (es)
AU (2) AU2016340072B2 (es)
CA (1) CA3001346A1 (es)
EA (1) EA036623B1 (es)
IL (2) IL258570B1 (es)
MX (2) MX2018004695A (es)
MY (1) MY193964A (es)
WO (1) WO2017066554A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001346A1 (en) * 2015-10-16 2017-04-20 Regeneron Pharmaceuticals, Inc. Stable protein compositions
AU2018368466A1 (en) * 2017-11-17 2020-06-18 Amgen Inc. VEGFR-Fc fusion protein formulations
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
EP3851096A4 (en) * 2018-09-10 2022-07-06 Samsung Bioepis Co., Ltd. LIQUID COMPOSITION COMPRISING A PROTEIN
CN112294760A (zh) * 2019-07-26 2021-02-02 张晋宇 一种液体制剂及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5018693A (en) * 1992-09-21 1994-04-12 Upjohn Company, The Sustained-release protein formulations
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
CA2512052C (en) * 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
ATE536861T1 (de) * 2003-06-26 2011-12-15 Control Delivery Sys Inc Bioerodierbare arzneimittelabgabesysteme mit verzögerter freisetzung
WO2006057859A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
LT2944306T (lt) * 2006-06-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu
US20100318193A1 (en) 2007-03-08 2010-12-16 Desai Tejal A Topographically engineered structures and methods for using the same in regenerative medicine applications
EP2164425B1 (en) 2007-03-16 2015-10-28 The Regents of The University of California Nanostructure surface coated medical implants and methods of using the same
PL2391419T3 (pl) * 2009-01-29 2019-12-31 Forsight Vision4, Inc. Dostarczanie leku do tylnego odcinka
US8623395B2 (en) * 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CN101559041B (zh) * 2009-05-19 2014-01-15 中国科学院过程工程研究所 粒径均一的多肽药物缓释微球或微囊制剂及制备方法
US8417452B2 (en) 2009-08-19 2013-04-09 General Motors Llc System for providing information to an operator of a vehicle
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
SG194155A1 (en) 2011-04-14 2013-11-29 Univ California Multilayer thin film drug delivery device and methods of making and using the same
JP6336442B2 (ja) 2012-05-30 2018-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性剤送達デバイス及びその製造方法と使用方法
WO2014039964A2 (en) 2012-09-10 2014-03-13 The Regents Of The University Of California Compounds and methods for modulating vascular injury
JP6783223B2 (ja) * 2014-07-14 2020-11-11 アムジェン インコーポレイテッド 結晶性抗体製剤
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
CA3001346A1 (en) * 2015-10-16 2017-04-20 Regeneron Pharmaceuticals, Inc. Stable protein compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US11951216B2 (en) 2011-11-18 2024-04-09 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Also Published As

Publication number Publication date
MY193964A (en) 2022-11-03
IL258570A (en) 2018-05-31
JP2018538243A (ja) 2018-12-27
CA3001346A1 (en) 2017-04-20
WO2017066554A1 (en) 2017-04-20
JP2021098742A (ja) 2021-07-01
CN108348462B (zh) 2021-10-15
CN108348462A (zh) 2018-07-31
AU2022200475B2 (en) 2023-09-14
IL310557A (en) 2024-03-01
IL258570B1 (en) 2024-03-01
JP2023025046A (ja) 2023-02-21
AU2022200475A1 (en) 2022-02-17
EP3362041A1 (en) 2018-08-22
JP7179112B2 (ja) 2022-11-28
EA201890979A1 (ru) 2018-10-31
US20180289623A1 (en) 2018-10-11
CN113827704A (zh) 2021-12-24
KR20180063311A (ko) 2018-06-11
AU2016340072B2 (en) 2021-10-28
AU2016340072A1 (en) 2018-05-10
BR112018007507A2 (pt) 2018-10-23
EA036623B1 (ru) 2020-12-01
JP6853245B2 (ja) 2021-03-31
MX2022003376A (es) 2022-04-12

Similar Documents

Publication Publication Date Title
MX2022003376A (es) Composiciones de proteinas estables.
NZ711546A (en) Drug delivery devices with drug-permeable component and methods
HRP20211415T1 (hr) Brzodjelujući pripravci inzulina
TW200637615A (en) Therapeutic peptide formulations with improved stability
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
MY188825A (en) High-concentration monoclonal antibody formulations
JP2014138843A5 (es)
AR094548A1 (es) Dispersión sólida físicamente estable
MX362275B (es) Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
WO2013078257A3 (en) Implantable solid-liquig drug delivery apparatus, formulations, and methods of use
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
MX2021012349A (es) Dispositivos y metodos de unidades multiples para administracion de farmacos.
MX2019014942A (es) Dispositivos de administracion de farmacos bioerosionables.
EP4233978A3 (en) Oral delivery of active drug substances
BR112015021446A2 (pt) métodos cirúrgicos empregando composições de peptídeo amfifílico purificado
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
EA201692392A1 (ru) Новая лекарственная форма мелоксикама
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
AU2015242791A1 (en) Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors
EP2745856A3 (en) Bioactive Compositions, Bioactive Eluting Devices and Methods of Use Thereof
MX2009013183A (es) Uso de la proteina de fusion taci-ig, tal como atacicept, para la elaboracion de un medicamento para tratar lupus eritematoso.
MX2020006886A (es) Sistema para suministro de medicamento.
EA202191570A1 (ru) Композиции для доставки терапевтических средств, способы их применения и получения